Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3120135 | 0.98 | GAA (0.33) | GAAHSD17B10CYP19A1EGLN3 | |
| SCHEMBL27605689 | 0.77 | DRD2 (0.40) | GAAHSD17B10 | |
| SCHEMBL10267744 | 0.75 | DRD2 (0.39) | GAAHSD17B10 | |
| SCHEMBL9567324 | 0.75 | GAA (0.31) | GAAHSD17B10 | |
| SCHEMBL12473005 | 0.73 | LTA4H (0.33) | LTA4H | |
| SCHEMBL9965894 | 0.70 | GAA (0.35) | GAAHSD17B10CYP19A1EGLN3 | |
| SCHEMBL4287716 | 0.69 | EGLN3 (0.39) | GAAHSD17B10EGLN3 | |
| Hydrochloric Acid SCHEMBL6787917 | 0.69 | CYP2B6 (0.44) | CYP19A1 | |
| SCHEMBL5892038 | 0.66 | CXCR4 (0.41) | LTA4H | |
| SCHEMBL3022129 | 0.66 | LTA4H (0.36) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-1997495-B1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
| EP-1608374-B9 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1997495-A1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | Actimis Pharmaceuticals, Inc., (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1608374-B1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | GAA 2388/4885HSD17B10 2192/4885CYP19A1 2437/4885 |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | CCR3, CCR1, CCR2 | GAA 4512/4885HSD17B10 2856/4885CYP19A1 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.